Sartorius Stedim Biotech SA
56S1
Company Profile
Business description
Sartorius Stedim Biotech is a leading provider of bioprocessing solutions. Its sells equipment and consumables for fermentation, filtration, fluid management, purification, and cell culture media for manufacturing biologic drugs and has a focus on single-use technology. It is a subsidiary of Sartorius AG, which has 71.5% ownership and 83% voting control. The business is geographically diverse, with 35% of sales from the Americas, 42% from Europe, the Middle East, and Africa, 15% from Asia excluding China, and 8% from China.
Contact
Otto-Brenner-Strasse 20
Goettingen37079
DEUT: +49 5513080
Sector
Healthcare
Stock type
Defensive
Industry
Medical Instruments & Supplies
Fiscal Year End
31 December 2025
Employees
9,961
Stocks News & Analysis
stocks
Most popular shares in SMSFs
With data showing the continued rise of SMSFs, we explore the top stock picks of individual investors
stocks
Will China strong arm BHP into lower iron ore prices?
Allegations that the Chinese government told steel mills to stop buying from BHP shake markets.
stocks
Chart of the Week: Where Morningstar sees attractive dividend yields in 26/27
Charts from the Australian Dividend Outlook show the sectors where they are abundant.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,264.30 | 8.50 | 0.09% |
| CAC 40 | 7,918.00 | 123.36 | -1.53% |
| DAX 40 | 24,241.46 | 369.79 | -1.50% |
| Dow JONES (US) | 45,479.60 | 878.82 | -1.90% |
| FTSE 100 | 9,427.47 | 81.93 | -0.86% |
| HKSE | 26,290.32 | 462.27 | -1.73% |
| NASDAQ | 22,204.43 | 820.20 | -3.56% |
| Nikkei 225 | 48,088.80 | 491.64 | -1.01% |
| NZX 50 Index | 13,467.26 | 103.60 | -0.76% |
| S&P 500 | 6,552.51 | 182.60 | -2.71% |
| S&P/ASX 200 | 8,958.30 | 9.20 | 0.10% |
| SSE Composite Index | 3,897.03 | 36.94 | -0.94% |